GlassScriptPhysician profile
Mel F Roca
NPI 1841427564
$13,192.25
in general payments reported to CMS, 2019-2025
58 companies · $2,310 in 2025
The $2,310 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,825 · 2020: $208 · 2021: $926 · 2022: $2,289 · 2023: $2,428 · 2024: $3,207 · 2025: $2,310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,916 · Education: $28.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,916.26 |
| Education | $28.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,414.44 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals LP | $1,279.07 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,153.89 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Aimmune Therapeutics, INC. | $777.45 | 2024-2025 | Zenpep |
| Pfizer INC. | $751.41 | 2019-2025 | |
| Amgen INC. | $737.70 | 2019-2024 | Prolia, Evenity, Repatha |
| Lilly USA, LLC | $669.24 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $626.68 | 2022-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Bayer Healthcare Pharmaceuticals INC. | $609.50 | 2021-2025 | |
| Gilead Sciences, INC. | $340.34 | 2019-2025 | Epclusa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $301.33 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $270.78 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $268.05 | 2019-2024 | Xarelto |
| Teva Pharmaceuticals USA, INC. | $224.61 | 2019-2025 | Austedo, Austedo Xr, Austedo Xr |
| Astellas Pharma US INC | $223.09 | 2019-2025 | Veozah |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mel Roca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.